LIGAND PHARMACEUTICALS (LGND)

US53220K5048 - Common Stock

69.98  -0.59 (-0.84%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
277.1M
48.66%		196.2M
-29.20%		131.314M
-33.07%		140.43M
6.94%
EBITDA
YoY % growth
130M
277.91%		54.5M
-58.08%		46.342M
-14.97%		86.464M
86.58%		N/AN/AN/AN/A
EBIT
YoY % growth
78.9M
806.90%		3M
-96.20%		9.821M
227.37%		47.124M
379.83%
Operating Margin
28.47%1.53%7.48%33.56%
EPS
YoY % growth
6.42
41.10%		4.28
-33.33%		6.10
42.52%		4.54
-25.51%		N/AN/AN/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		0.84
-62.96%
Revenue
Q2Q % growth		28.482M
-35.24%		N/AN/AN/AN/A
EBITDA
Q2Q % growth		14.126MN/AN/AN/AN/A
EBIT
Q2Q % growth		-408K
-102.87%		N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 1.38
1.47%		0.670.71104.76%
Q3 2023
Q2Q % growth		 1.02
-22.14%		0.620.4063.93%
Q2 2023
Q2Q % growth		 1.42
37.86%		0.650.77117.61%
Q1 2023
Q2Q % growth		 2.28
293.10%		0.911.37150.03%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 28.101M
3.89%		26.23M1.871M7.13%
Q3 2023
Q2Q % growth		 32.87M
-44.50%		27.73M5.14M18.54%
Q2 2023
Q2Q % growth		 26.37M
-54.08%		26.248M122K0.46%
Q1 2023
Q2Q % growth		 43.98M
20.43%		34.718M9.262M26.68%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% -2.59% 0% 4.03%
Revenue0% 20.18% 0% 0.01%